CN101257901A - 可溶性鸟苷酸环化酶活化剂用于治疗再输注损伤的用途 - Google Patents
可溶性鸟苷酸环化酶活化剂用于治疗再输注损伤的用途 Download PDFInfo
- Publication number
- CN101257901A CN101257901A CNA200680024418XA CN200680024418A CN101257901A CN 101257901 A CN101257901 A CN 101257901A CN A200680024418X A CNA200680024418X A CN A200680024418XA CN 200680024418 A CN200680024418 A CN 200680024418A CN 101257901 A CN101257901 A CN 101257901A
- Authority
- CN
- China
- Prior art keywords
- medicine
- reperfusion damage
- chemical compound
- purposes
- guanylate cyclase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (7)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005031576A DE102005031576A1 (de) | 2005-07-06 | 2005-07-06 | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Reperfusionsschäden |
DE102005031576.3 | 2005-07-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101257901A true CN101257901A (zh) | 2008-09-03 |
Family
ID=37433912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA200680024418XA Pending CN101257901A (zh) | 2005-07-06 | 2006-07-06 | 可溶性鸟苷酸环化酶活化剂用于治疗再输注损伤的用途 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20090298822A1 (zh) |
EP (1) | EP1901730A1 (zh) |
JP (1) | JP2009500365A (zh) |
KR (1) | KR20080033238A (zh) |
CN (1) | CN101257901A (zh) |
AU (1) | AU2006286896A1 (zh) |
BR (1) | BRPI0612685A2 (zh) |
CA (1) | CA2614088A1 (zh) |
DE (1) | DE102005031576A1 (zh) |
IL (1) | IL188584A0 (zh) |
MX (1) | MX2008000276A (zh) |
RU (1) | RU2432948C2 (zh) |
WO (1) | WO2007025595A1 (zh) |
ZA (1) | ZA200800025B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103180327A (zh) * | 2010-07-09 | 2013-06-26 | 拜耳知识产权有限责任公司 | 稠环的4-氨基嘧啶及其作为可溶性鸟甘酸环化酶的刺激物的用途 |
CN103906752A (zh) * | 2011-07-06 | 2014-07-02 | 拜耳知识产权有限责任公司 | 杂芳基取代的吡唑并吡啶及其用作可溶性鸟苷酸环化酶刺激剂的用途 |
CN105026405A (zh) * | 2013-03-01 | 2015-11-04 | 拜耳制药股份公司 | 苄基-取代的吡唑并吡啶及其用途 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007026392A1 (de) * | 2007-06-06 | 2008-12-11 | Bayer Healthcare Ag | Lösungen für die Perfusion und Konservierung von Organen und Geweben |
US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US173514A (en) * | 1876-02-15 | Improvement in call-bells | ||
DK1095016T3 (da) * | 1998-07-08 | 2006-03-13 | Sanofi Aventis Deutschland | Svovlsubstituerede sulfonylaminocarboxylsyre-N-arylamider, deres fremstilling, deres anvendelse og farmaceutiske præparater omfattende dem |
DE19834044A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19943635A1 (de) * | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
AR031176A1 (es) * | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
WO2003040332A2 (en) * | 2001-11-06 | 2003-05-15 | Buck Institute | Neuroglobin is up-regulated by and protects neuronsfrom hypoxic-ischemic injury |
DE10220570A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
DE10351903A1 (de) * | 2003-11-06 | 2005-06-09 | Bayer Healthcare Ag | Neue Kombination |
WO2005077005A2 (en) * | 2004-02-04 | 2005-08-25 | The General Hospital Corporation | Enhancing the effectiveness of an inhaled therapeutic gas |
WO2006037491A1 (en) * | 2004-10-05 | 2006-04-13 | Bayer Healthcare Ag | A guanylane cyclase stimulator and nitric oxide for treating bronchoconstriction and pulmonary vasoconstriction |
-
2005
- 2005-07-06 DE DE102005031576A patent/DE102005031576A1/de not_active Withdrawn
-
2006
- 2006-07-06 WO PCT/EP2006/006600 patent/WO2007025595A1/de active Application Filing
- 2006-07-06 JP JP2008519861A patent/JP2009500365A/ja active Pending
- 2006-07-06 CN CNA200680024418XA patent/CN101257901A/zh active Pending
- 2006-07-06 BR BRPI0612685-5A patent/BRPI0612685A2/pt not_active IP Right Cessation
- 2006-07-06 US US11/922,838 patent/US20090298822A1/en not_active Abandoned
- 2006-07-06 RU RU2008103549/15A patent/RU2432948C2/ru not_active IP Right Cessation
- 2006-07-06 AU AU2006286896A patent/AU2006286896A1/en not_active Abandoned
- 2006-07-06 KR KR1020087000280A patent/KR20080033238A/ko not_active Application Discontinuation
- 2006-07-06 CA CA002614088A patent/CA2614088A1/en not_active Abandoned
- 2006-07-06 MX MX2008000276A patent/MX2008000276A/es not_active Application Discontinuation
- 2006-07-06 EP EP06818217A patent/EP1901730A1/de not_active Ceased
-
2008
- 2008-01-02 ZA ZA200800025A patent/ZA200800025B/xx unknown
- 2008-01-03 IL IL188584A patent/IL188584A0/en unknown
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103180327A (zh) * | 2010-07-09 | 2013-06-26 | 拜耳知识产权有限责任公司 | 稠环的4-氨基嘧啶及其作为可溶性鸟甘酸环化酶的刺激物的用途 |
CN103906752A (zh) * | 2011-07-06 | 2014-07-02 | 拜耳知识产权有限责任公司 | 杂芳基取代的吡唑并吡啶及其用作可溶性鸟苷酸环化酶刺激剂的用途 |
CN105026405A (zh) * | 2013-03-01 | 2015-11-04 | 拜耳制药股份公司 | 苄基-取代的吡唑并吡啶及其用途 |
CN105026405B (zh) * | 2013-03-01 | 2017-08-08 | 拜耳制药股份公司 | 苄基‑取代的吡唑并吡啶及其用途 |
Also Published As
Publication number | Publication date |
---|---|
IL188584A0 (en) | 2008-06-05 |
EP1901730A1 (de) | 2008-03-26 |
KR20080033238A (ko) | 2008-04-16 |
MX2008000276A (es) | 2008-03-19 |
JP2009500365A (ja) | 2009-01-08 |
ZA200800025B (en) | 2009-09-30 |
AU2006286896A1 (en) | 2007-03-08 |
US20090298822A1 (en) | 2009-12-03 |
RU2008103549A (ru) | 2009-08-20 |
BRPI0612685A2 (pt) | 2010-11-30 |
DE102005031576A1 (de) | 2007-01-25 |
RU2432948C2 (ru) | 2011-11-10 |
CA2614088A1 (en) | 2007-03-08 |
WO2007025595A1 (de) | 2007-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH02255617A (ja) | 虚血前後の心筋不整脈および細動の軽減用組成物 | |
CN101257901A (zh) | 可溶性鸟苷酸环化酶活化剂用于治疗再输注损伤的用途 | |
CN104619710A (zh) | 用于治疗再灌注损伤的氧杂二环庚烷和氧杂二环庚烯 | |
FR3095755A1 (fr) | Nouveaux médicaments cytoprotecteurs | |
JP2574585B2 (ja) | 再潅流損傷の防止又は制限のための薬剤 | |
CN110167542A (zh) | 1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法 | |
ES2507569T3 (es) | Agente profiláctico o terapéutico contra enfermedades oculares acompañadas de un trastorno del nervio óptico | |
CA3166379A1 (en) | Inhibitors of glutathione s-transferases (gsts) and nad(p)h:quinone oxidoreductase 1 (nqo1), pharmaceutical compositions, and uses in managing cancer | |
JP2007538016A (ja) | 医薬品中におけるカウレン類化合物の使用 | |
US20120251634A1 (en) | Traditional chinese drug comprising danshen extracts and sanqi extracts and use thereof | |
US7635691B2 (en) | Use of CDP-choline for the prophylactic treatment of cerebral ischemia | |
TW200829261A (en) | Method for controlling angiogenesis in animals | |
CN105497022A (zh) | 奥拉西坦或左旋奥拉西坦在制药领域中的新应用 | |
CN104582704A (zh) | 含伊马替尼或其药学上可接受的盐作为有效成分的用于治疗或预防血管渗透性疾病的组合物 | |
RU2252754C2 (ru) | Применение карипорида для уменьшения нежелательных воздействий макролидных антибиотиков при ишемии и реперфузии сердца | |
RU2499593C1 (ru) | Противоишемическое средство | |
WO2010146551A2 (en) | Orally disintegrating compositions comprising antihypertensive agents | |
RU2333202C2 (ru) | 2-(бутил-1-сульфониламино)-n-[1(r)-(6-метоксипиридин-3-ил)-пропил]бензамид, его применение в качестве лекарственного средства, а также содержащие его фармацевтические композиции | |
RU2469740C2 (ru) | Средство для снижения побочного эффекта противоракового лекарственного средства | |
JP2004331502A (ja) | 視神経細胞保護剤 | |
CN109820855A (zh) | 常山酮在制备用于治疗和预防缺血性心脏病药物中的应用 | |
CN101940562B (zh) | 一种非布索坦或其可药用盐固体制剂及其制备方法 | |
CN102151282B (zh) | 环烯醚萜苷及其衍生物作为纤溶酶抑制剂的应用及其药物组合物 | |
CN108125914A (zh) | 一种奥美沙坦酯氢氯噻嗪复方制剂 | |
WO2018090358A1 (zh) | 匹诺塞林在制备抗脑出血药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1124525 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: BAYER SCHERING PHARMA AG Free format text: FORMER OWNER: BAYER HEALTHCARE AG Effective date: 20091204 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20091204 Address after: Berlin Applicant after: Bayer Schering Pharma AG Address before: Germany Leverkusen Applicant before: Bayer Healthcare AG |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20080903 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1124525 Country of ref document: HK |